stars 1 stars 2 stars 3

CELLforCURE by SEQENS, based near Paris, is a leader in the manufacturing of Advanced Therapy Medicinal Products (ATMPs), specialized in both autologous and allogeneic cell and gene therapy solutions. With over a decade of expertise, we provide comprehensive end-to-end services, from Phase I to full-scale commercial production. Our cutting-edge “one-stop-shop” facility spans 10,000 sqm, including 2,200 sqm of GMP-certified production areas and 7 independent manufacturing lines, each equipped with 8 cleanrooms, ensuring maximum safety and compliance for every product. As a trusted comprehensive solution provider, we facilitate seamless project development, leveraging in-house Quality Control for 90% of processes to deliver drug products. With a unique blend of CDMO heritage and proven commercial manufacturing expertise, CELLforCURE is the ideal partner to help bring your innovative therapies to life, transforming groundbreaking ideas into commercial success.

Website https://cellandgene.seqens.com/
Revenue $1.1 billion
Employees 121 (72 on RocketReach)
Founded 2014
Industry Biotechnology Research

CELLforCURE by Seqens Questions

The CELLforCURE by Seqens annual revenue was $1.1 billion in 2026.

Marc-Olivier Mignon is the CEO of CELLforCURE by Seqens.

72 people are employed at CELLforCURE by Seqens.

Top CELLforCURE by Seqens Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users